drugset / Trial / NCT04575064
An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY
Phase 2/3
Withdrawn
Professor Dr. Bernd Mühlbauer
Institut National de la Santé Et de la Recherche Médicale, France · collabWorld Health Organization · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is an adaptive, randomized, open-label, controlled clinical trial, performed worldwide in collaboration with WHO and INSERM.
Timeline
- Start
- 2020-06-29
- Primary completion
- 2022-03
- Completion
- 2022-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Remdesivir | Small molecule | 100 mg | Intravenous |